Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) ALICE FOSTER HEAD PRESCRIBING ADVISER QIPP PRESCRIBING LEAD

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) ALICE FOSTER HEAD PRESCRIBING ADVISER QIPP PRESCRIBING LEAD"

Transcription

1 Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) ALICE FOSTER HEAD PRESCRIBING ADVISER QIPP PRESCRIBING LEAD

2 QIPP Improving Prescribing Installation of GRASP-AF in 106 NHS Devon practices by end of June 2011 Practices to be able to run first query July 2011 onwards AF prevalence in NHS Devon is 1.97% but up to 3.8% in some practices

3 Mid Devon Consortium AF prevalence Prescriber Name Total Patients Total Patients aged over 65 % patients over 65 Atrial Fibrillation Register 09/10 AF prevalence QOF 09/10 BAMPTON SURGERY 3,994 1, % % BLACKDOWN PRACTICE 7,270 1, % % BOW SURGERY 2, % % BRAMBLEHAIES SURGERY 6,430 1, % % CASTLE PLACE PRACTICE 15,096 2, % % CHAGFORD HEALTH CENTRE 3, % % CHERITON BISHOP SURGERY 4,641 1, % % CHIDDENBROOK SURGERY 7,271 1, % % CLARE HOUSE 10,461 2, % % COLLEGE SURGERY PARTNERSHIP 14,638 2, % % EXE VALLEY PRACTICE 1, % % HATHERLEIGH MEDICAL CENTRE 2, % % MID DEVON MEDICAL PRACTICE 4,824 1, % % MORETONHAMPSTEAD HEALTH CENTRE 3, % % NEWCOMBES SURGERY 6,905 1, % % NORTH TAWTON MEDICAL PRACTICE 2, % % OKEHAMPTON MEDICAL CENTRE 12,153 2, % % OKEMENT PRIMARY CARE CENTRE 222 1, % % SAMPFORD PEVERELL SURGERY 1, % % WYNDHAM HOUSE SURGERY 3, % %

4

5 Background to GRASP-AF Query and risk stratification tool available for use with all GP clinical systems in England Developed collaboratively and piloted by the West Yorkshire Cardiovascular Network, the Leeds Arrhythmia team and PRIMIS+, as part of the AF in primary care national priority projects, made available nationally through NHS Improvement. This tool should be used as part of a systematic approach to the identification, diagnosis and optimal management of patients with AF to reduce their risk of stroke.

6 Stroke management and stroke prevention are major priority areas for the NHS. This has been identified as one of the recommended interventions on NHS Evidence - Quality and Productivity Priorities. Atrial fibrillation (AF) is a major cause of stroke, accounting for some 14% of all strokes. Atrial fibrillation also increases the risk and severity of stroke. Recognition and optimal treatment of AF is of particular importance as strokes due to AF are eminently preventable.

7 Prevalence rate in primary care is 1.2%, which equates to just over 600,000 patients in England have AF 12,500 strokes per year are thought to be directly attributable to AF The estimated total cost of maintaining one patient on warfarin for one year, including monitoring, is 383 The cost per stroke due to AF is estimated to be 11,900 in the first year after stroke occurrence NICE estimate that approximately 40% of patients in whom warfarin is indicated are not receiving it, amounting to some 166,000 patients nationally.

8 What does GRASP-AF do? Provides a set of MIQUEST queries to identify, for your practice, patients with a diagnosis of AF who are not on warfarin The GRASP - AF tool will calculate their stroke risk using the validated CHADS2 scoring system The tool will highlight patients with a CHADS2 score of 2 or more not receiving warfarin who would benefit from review to assess the issue of anti-coagulation The tool does not assess contraindications to warfarin, the decision whether or not to start warfarin remains a clinical one.

9 "Treating these patients with Warfarin could prevent 6,000 stokes nationally and save 4,000 lives each year (Nice 2006) The GRASP-AF toolkit will apply a CHADS2 stroke risk stratification score to your AF patients and identify those patients with AF at a high risk of stroke and not on warfarin. Experience has shown, after registering and downloading the GRASP-AF tool, this takes just a few minutes to run on the GP clinical system. Initial findings show that around five patients per GP benefit from being reviewed with a view to commencing warfarin.

10 What is a CHADS2 score? CHADS2 assigns one point each for Congestive heart failure Hypertension Age 75 or older Diabetes mellitus and two points for a previous Stroke (S2) or transient ischemic attack Patients with AF with a CHADS2 score of 2 or more should be treated with warfarin

11 Annual stroke risk if not on anticoagulants Points Annual Stroke Risk 0 1.9% 1 2.8% 2 4.0% 3 5.9% 4 8.5% % %

12 GRASP AF (ATRIAL FIBRILLATION) CHOOSE ANOTHER LIBRARY ATRIAL FIBRILLATION HOME ATRIAL FIBRILLATION & CHADS SCORE WARFARIN NO PERCENT Total No of Patients currently registered with Practice 5342 Total No of Patients with Atrial Fibrillation / Flutter % % of practice population aged 65+ with Atrial Fibrillation / Flutter 6.12% Risk Profile for Thromboembolism NO PERCENT CHADS2 Score = % CHADS2 Score = % CHADS2 Score > % TOTAL %

13 GRASP AF (ATRIAL FIBRILLATION) CHOOSE ANOTHER LIBRARY ATRIAL FIBRILLATION HOME ATRIAL FIBRILLATION & CHADS SCORE WARFARIN Warfarin use in high risk patients (CHADS2 > 1) NO PERCENT Patients on warfarin % Patients not on warfarin % % of practice population aged 65+ with Atrial Fibrillation / Flutter 6.12% Patients on warfarin and anti-platelet agents in CHADS2 groups None Anti-platelet Warfarin Both CHADS2 Score = CHADS2 Score = CHADS2 Score >

14 Line by line list of all patients with atrial fibrillation Those with CHADS2 score greater than 1 and not on warfarin highlighted in red Filters to find specific groups of patients Graphs including view of warfarin use, reasons for not prescribing, against CHADS2 score

15

16

17

18 Making a difference After running the GRASP-AF tool, upload your data to CHART-Online which will enable you to save your initial baseline position. Following review for optimal therapy, further uploads will demonstrate progress to reducing risk of stroke in patients with AF within your practice and enable you to anonymously compare your results online with other practices, PCTs, Cardiac and Stroke Networks and SHAs. Run the GRASP-AF tool on an annual basis as an active CHADS2 risk stratification review for your AF patients to support the management of stroke prevention.

19

20

21

22 How will this be done in NHS Devon? 1. Each GP practice nominates a PRIMIS+ contact practice manager, admin staff or IT 2. PRIMIS+ contact registers on PRIMIS+ Profile Centre This gives Level 1 access to PRIMIS+ 3. Once registered practice provides name, and practice code of PRIMIS+ contact to Rachel Browse at NHS Devon prescribing. 4. PRIMIS+ will upgrade practice user to Level 2.

23 5. NHS Devon IT engineers will contact practice to come and install CHART and GRASP-AF software, map folders, set up Excel security on one desktop PC in the practice. Check that software runs correctly 6. Practice can then run query and save results to main practice shared drive. 7. Software can be installed on more than one PC but once query is run the data is on the shared drive so can be easily accessed

24 8. GP s will then be able to see results from query and review patients identified. 9. Uploaded data is anonymised but gives practice and PCT comparable information. 10.Guidance and information will be provided from the Peninsula Heart and Stroke Network 11.After 6-12 months the query can be run again to identify the change

25 What will this cost each practice?

26 The software is NHS and is free to download for those registered with PRIMIS+. IT support will be given by NHS Devon. Guidance and supporting information from the Peninsula Heart and Stroke Network Supported by NHS Devon prescribing team pharmacists and technicians

27 NO FINANCIAL COST TO PRACTICE BUT SIGNIFICANT POTENTIAL PATIENT BENEFIT WITH REDUCED RISK OF STROKE

28

29 SAFER PRESCRIBING CHOOSE ANOTHER LIBRARY SAFER PRESCRIBING HOME POSSIBLE INAPPROPRIATE DRUG FOR AGE POSSIBLE INAPPROPRIATE PRESCRIBING POSSIBLE OVERLOOKED SAFETY INFORMATION POSSIBLE INADEQUATE MONITORING PART 1 POSSIBLE OVERLOOKED LABORATORY TESTS POSSIBLE INADEQUATE MONITORING PART 2 The Safer Prescribing Library allows practices to examine their current prescribing to identify issues or even systems which might need attention.

Making the Health Check work for you

Making the Health Check work for you Making the Health Check work for you Atrial Fibrillation and the GRASP toolkit (Guidance on Risk Assessment and Stroke Prevention ) Dr. Indira Natarajan Consultant Stroke Physician University Hospital

More information

Survey into the diagnosis, management and treatment of patients with Atrial Fibrillation

Survey into the diagnosis, management and treatment of patients with Atrial Fibrillation FREEDOM OF INFORMATION RESPONSE Reference: 2011-135 From: Commercial organisation Date: 20 May 2011 Subject: Atrial Fibrillation REQUEST / RESPONSE FREEDOM OF INFORMATION REQUEST Survey into the diagnosis,

More information

GRASP-AF Coming to a PCT near you.

GRASP-AF Coming to a PCT near you. GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation

More information

GRASP-AF Audit Tool Instructional Guide

GRASP-AF Audit Tool Instructional Guide GRASP-AF Audit Tool Instructional Guide GRASP-AF is funded and supported by NHS Improving Quality. The GRASP-AF tool has been developed by PRIMIS in partnership with NHSIQ. Document reviewed by PRIMIS

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,

More information

Service Specification Template Department of Health, updated June 2015

Service Specification Template Department of Health, updated June 2015 Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st

More information

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 275: Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation 1

More information

Commissioning effective anticoagulation services for the future

Commissioning effective anticoagulation services for the future anticoagulation ( ) UK Commissioning effective anticoagulation services for the future A resource pack for commissioners The development of this commissioning toolkit was supported by Bayer HealthCare.

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE

FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 06/06/2012 Review Date 06/06/2014 Version 1.1 EQIA Yes /

More information

Endorsement Summary: Cardiovascular Measures

Endorsement Summary: Cardiovascular Measures January 2012 Purpose of the Project The human and financial costs of cardiovascular disease are enormous. Heart disease is the leading cause of death for men and women in the United States and was estimated

More information

Prevention of stroke in patients with atrial fibrillation

Prevention of stroke in patients with atrial fibrillation www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment

More information

Dorset Cardiac Centre

Dorset Cardiac Centre P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006

More information

Anticoagulants in Atrial Fibrillation

Anticoagulants in Atrial Fibrillation Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives

More information

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.

Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction

More information

Costs and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF

Costs and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF Costs and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF Marion Kerr Insight Health Economics for NHS We would like to acknowledge PRIMIS who

More information

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION

NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance

More information

Medicines Optimisation Supporting information for the prototype dashboard

Medicines Optimisation Supporting information for the prototype dashboard Medicines Optimisation Supporting information for the prototype dashboard 1 NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information Nursing Policy Commissioning Development

More information

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Updates to the Alberta Drug Benefit List. Effective January 1, 2016 Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

Treatments to Restore Normal Rhythm

Treatments to Restore Normal Rhythm Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent

More information

Breakfast symposium: From hospital to home - the focus on the patient

Breakfast symposium: From hospital to home - the focus on the patient Breakfast symposium: From hospital to home - the focus on the patient Nadya Hamedi DARZI Fellow UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee

More information

Objectives of Session

Objectives of Session Objectives of Session Project Background Why the need Decision Support Tool summary of key evidence Promotion Key Messages Project Background Grasp AF Audit Initial Grasp AF project undertaken in NHS Buckinghamshire

More information

All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation

All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation October 2013 This report has been prepared by a multiprofessional collaborative group, with support

More information

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)

More information

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About

More information

2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF)

2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF) 2015/16 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF) Guidance for GMS contract 2015/16 March 2015 Publications Gateway Reference Number 03099 Contents Section 1 Introduction

More information

Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners

Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners Dabigatran in Atrial Fibrillation Question and Answers document to inform commissioners West Midlands Commissioning Support Unit, Birmingham University /New Medicines Evaluation Unit, Keele University

More information

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement

Birmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners

More information

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:

More information

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

Healthy Futures Programme. West Yorkshire Atrial Fibrillation Anticoagulation Strategy

Healthy Futures Programme. West Yorkshire Atrial Fibrillation Anticoagulation Strategy Healthy Futures Programme West Yorkshire Atrial Fibrillation Anticoagulation Strategy Table of Contents 1.0 Executive Summary... 3 2.0 How to Read This Document... 4 3.0 Context & Scene Setting... 6 4.0

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Intelligent Monitoring Report. Greenford Avenue Family Health Practice 322 Greenford Avenue London W7 3AH

Intelligent Monitoring Report. Greenford Avenue Family Health Practice 322 Greenford Avenue London W7 3AH Greenford Avenue Family Health Practice 322 Greenford Avenue London W7 3AH Intelligent Monitoring (IM) Report GP IM is an initial list of 37 indicators that currently cover three of our five key questions

More information

Stroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures

Stroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures Stroke Prevention In Atrial Fibrillation Integrated Care Clinics Patient Reported Outcome Measures Apodi Healthcare Mathew s Practice, Sheffield. June & July 2013 This SPAF Integrated Care Clinic programme

More information

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues

NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is

More information

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia

More information

WARFARIN USE IN PATIENTS WITH ATRIAL FIBRILLATION: IS THERE A DISPARITY IN CARE AMONG PATIENTS MANAGED BY ATTENDING PHYSICANS COMPARED TO RESIDENTS?

WARFARIN USE IN PATIENTS WITH ATRIAL FIBRILLATION: IS THERE A DISPARITY IN CARE AMONG PATIENTS MANAGED BY ATTENDING PHYSICANS COMPARED TO RESIDENTS? Rose Tompkins Medicine PGY1 IRB Protocol February 18, 2011 WARFARIN USE IN PATIENTS WITH ATRIAL FIBRILLATION: IS THERE A DISPARITY IN CARE AMONG PATIENTS MANAGED BY ATTENDING PHYSICANS COMPARED TO RESIDENTS?

More information

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia

More information

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes

More information

Newcastle, North Tyneside and Northumberland Guidelines on Antiplatelet Therapy

Newcastle, North Tyneside and Northumberland Guidelines on Antiplatelet Therapy Clinical Guidelines Guideline Number: NoT 14 (1 of 2) Newcastle, North Tyneside and Northumberland Guidelines on Antiplatelet Therapy Ratified by: NHS North of Tyne Commissioning Integrated Governance

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

S1. Which of the following age categories do you fall into? Please select one answer only. 18-44 years of age. 45-64 years of age. 65-74 years of age

S1. Which of the following age categories do you fall into? Please select one answer only. 18-44 years of age. 45-64 years of age. 65-74 years of age Supplemental Materials Supplemental Methods Patient Survey We are presently conducting a market research study to help us better understand some of the challenges experienced by patients taking anticoagulants

More information

A pocket guide to current guidelines and recommendations STROKE PREVENTION. in Atrial Fibrillation

A pocket guide to current guidelines and recommendations STROKE PREVENTION. in Atrial Fibrillation A pocket guide to current guidelines and recommendations STROKE PREVENTION in Atrial Fibrillation 2 STROKE PREVENTION in Atrial Fibrillation A pocket guide to current guidelines and recommendations STROKE

More information

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban)

An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Sabiha Fatima Hussaini Sabiha.hussaini@salisbury.nhs.uk An Audit of the Documentation and Correct Referral of Patients on Initiation of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) April

More information

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning

More information

Introduction. Background to this event. Raising awareness 09/11/2015

Introduction. Background to this event. Raising awareness 09/11/2015 Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness

More information

What are the PH interventions the NHS should adopt?

What are the PH interventions the NHS should adopt? What are the PH interventions the NHS should adopt? South West Clinical Senate 15 th January, 2015 Debbie Stark, PHE Healthcare Public Health Consultant Kevin Elliston: PHE Consultant in Health Improvement

More information

Atrial Fibrillation The Basics

Atrial Fibrillation The Basics Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation

More information

9/5/14. Objectives. Atrial Fibrillation (AF)

9/5/14. Objectives. Atrial Fibrillation (AF) Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three

More information

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with

More information

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014

RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 2014 1. 2. RAW PREVALENCE FOR NORTHERN IRELAND AS AT 31 MARCH 214 3.1 Coronary Heart Disease (CHD) 3.2 Heart Failure 1 3.3 Heart Failure 3 (heart failure due to Left Ventricular Systolic Dysfunction) 3.4 Stroke

More information

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Issued: May 2012 guidance.nice.org.uk/ta256 NICE has accredited the process used by the Centre for Health

More information

National Quality and Outcomes Framework Statistics for England 2006/07

National Quality and Outcomes Framework Statistics for England 2006/07 National Quality and Outcomes Framework Statistics for England 26/7 This bulletin presents a summary of data from the national Quality and Outcomes Framework (QOF) during 26/7. The QOF was first implemented

More information

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR)

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Development feedback report on piloted indicator(s) QOF indicator area: Heart failure cardiac rehabilitation

More information

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation

More information

Current and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012

Current and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012 Current and new oral Anti-coagulation Lancashire and Cumbria Network 2 February 2012 Question Warfarin is an abbreviation What does the W stand for? What is this plant and what is the connection with warfarin?

More information

Remote Data Extraction Policy and Procedure

Remote Data Extraction Policy and Procedure Remote Data Extraction Policy and Procedure Prepared by PRIMIS June 2015 The University of Nottingham. All rights reserved. Contents 1. Introduction... 3 2. Purpose and scope... 3 3. Policy Statement...

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015 The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation

Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation Survey of Canadian Physicians Use of anti-thrombotic therapy for Atrial Fibrillation On the following pages are a number of questions asking about the conditions under which you would prescribe anticoagulation

More information

Department of Health. Rheynn Slaynt. Clinical Recommendations Committee

Department of Health. Rheynn Slaynt. Clinical Recommendations Committee Department of Health Rheynn Slaynt Clinical Recommendations Committee Recommendation 12/12 The Isle of Man Department of Health will provide as a Restricted Priority not a first-line treatment, Dabigatran

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Bridging the Gap: How to Transition from the NOACs to Warfarin

Bridging the Gap: How to Transition from the NOACs to Warfarin Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Summary of QOF indicators

Summary of QOF indicators Summary of QOF indicators Clinical domain Atrial fibrillation (AF) AF001. The contractor establishes and maintains a register of patients with atrial fibrillation AF002. The percentage of patients with

More information

Which Drugs to Use? Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Which Drugs to Use? Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Which Drugs to Use? Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE: Support provided

More information

Transient Ischemic Attack (TIA) Diagnostic Pathway

Transient Ischemic Attack (TIA) Diagnostic Pathway Key Primary Care Secondary Care Transient Ischemic Attack (TIA) Diagnostic Pathway Patient presents to GP or A&E with Acute Neurological symptoms Click on the hyperlinks in the pathway to access the supporting

More information

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is

More information

The. Report. The Stroke Prevention in Atrial Fibrillation Expert Report

The. Report. The Stroke Prevention in Atrial Fibrillation Expert Report UK/DBG-121331 Date of preparation: June 2012 The Stroke Prevention in Atrial Fibrillation Expert Report The S E Report A UK report for media and parliamentarians June 2012 This report was authored by an

More information

The Prevent Defense Against Stroke: Preventing a Second Stroke or Transient Ischemic Attack

The Prevent Defense Against Stroke: Preventing a Second Stroke or Transient Ischemic Attack P A T I E N T V E R S I O N The Prevent Defense Against Stroke: Preventing a Second Stroke or Transient Ischemic Attack Sponsored by Support for this activity has been provided through an educational grant

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline

PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to guide clinicians on use of novel anticoagulants for stroke

More information

Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources

Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources Leveraging EMR Data to Better Understand Local Market Potential and the Deployment of Commercial Resources James Charnetski, Practice Leader Commercial Analytics & Effectiveness Quintiles Integrated Healthcare

More information

Guidelines for the Management of Oral Anticoagulants (Vitamin K Antagonists) During Invasive Procedures

Guidelines for the Management of Oral Anticoagulants (Vitamin K Antagonists) During Invasive Procedures Guidelines for the of Oral Anticoagulants (Vitamin K Antagonists) During Invasive Procedures These guidelines provide recommendations for patients on long-term oral anticoagulants who require an elective

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation STA REPORT This report was commissioned by the NIHR HTA Programme as project number 10/75 Title: Rivaroxaban

More information

Rising to the challenge: Delivering QIPP by preventing AF-related stroke. Foreword

Rising to the challenge: Delivering QIPP by preventing AF-related stroke. Foreword 2 Foreword Rising to the challenge: Delivering QIPP by preventing AF-related stroke Opportunities to improve the quality, safety and cost-effectiveness of NHS services that reduce the risk of stroke in

More information

A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF)

A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF) A PATIENT S GUIDE TO STROKE AND ATRIAL FIBRILLATION (AF) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects,

More information

Reducing Adverse Drug Events With Anti Coagulation Clinics. McFarland Clinic. McFarland Protime Clinic 09/05/12

Reducing Adverse Drug Events With Anti Coagulation Clinics. McFarland Clinic. McFarland Protime Clinic 09/05/12 Reducing Adverse Drug Events With Anti Coagulation Clinics Dr. Donald Skinner, MD McFarland Clinic 182 Physicians (149 Shareholders) 40 Mid Level Providers 13 Administrators/Executive Directors 1,200 Support

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Atrial Fibrillation, Stroke Prevention Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that rivaroxaban be

More information

Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE 1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Guideline title SCOPE Hypertension: clinical management of primary hypertension in adults 1.1 Short title Hypertension (partial update) 2 The remit

More information

Atrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation

Atrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation Quick reference guide Issue date: June 2006 Atrial fibrillation The management of atrial fibrillation Developed by the National Collaborating Centre for Chronic Conditions Contents Contents Patient-centred

More information

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,

More information

Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid

Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid Atrial fibrillation (non-valvular) and reducing the risk of a stroke Management Options Brief Decision Aid Atrial fibrillation (AF) increases your risk of having a stroke (a blood clot in the brain). From

More information

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of

More information

Cardiovascular disease Key contact/author: Dr Veena de Souza, Consultant in Public Health, Buckinghamshire County Council

Cardiovascular disease Key contact/author: Dr Veena de Souza, Consultant in Public Health, Buckinghamshire County Council Cardiovascular disease Key contact/author: Dr Veena de Souza, Consultant in Public Health, Buckinghamshire County Council Introduction Cardiovascular disease (CVD) includes heart disease and stroke. It

More information